WhiteOak Capital Pharma and Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended)
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return IndexCheck Portfolio Overlap →
NAV: ₹16.37+0.12%
22 Oct 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for WhiteOak Capital Pharma and Healthcare Fund Direct-Growth.
Market Cap Distribution
Large Cap (32.1%)
Mid Cap (24.5%)
Small Cap (43.3%)
Historical Asset Allocation
| Asset | 30 Sep 2026 | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 |
|---|---|---|---|---|---|---|
| Equity | 91.43% | 99.31% | 99.20% | 92.61% | 99.10% | 99.17% |
| Debt | 8.04% | 5.11% | 5.90% | 7.67% | 7.95% | 7.21% |
| Others (incl. cash) | 0.53% | -4.42% | -5.09% | -0.28% | -7.04% | -6.38% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
60
P/E Ratio
50.96
P/B Ratio
7.25
Top Holding %
7.73%
Top 5 Holdings %
28.83%
Top 10 Holdings %
43.98%
AUM
₹1,003 Cr
Expense Ratio
1.07%
Since Inception
19.95%
Max Drawdown
-0.15%
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | Healthcare | 83,411 | 77.5 | 7.73% | -0.72%↓ |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 3,62,534 | 65.86 | 6.57% | -0.83%↓ |
| Torrent Pharmaceuticals Ltd. | Healthcare | 1,20,829 | 58 | 5.78% | -1.00%↓ |
| Laurus Labs Ltd. | Healthcare | 1,83,009 | 36.24 | 3.61% | -0.17%↓ |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 42,590 | 34.78 | 3.47% | -1.26%↓ |
| Cipla Ltd. | Healthcare | 2,53,088 | 34.07 | 3.40% | 0.14%↑ |
| Sai Life Sciences Ltd. | Healthcare | 1,99,211 | 30.37 | 3.03% | -0.29%↓ |
| Ipca Laboratories Ltd. | Healthcare | 1,38,311 | 26.65 | 2.66% | 0.00%↑ |
| Zydus Lifesciences Ltd. | Healthcare | 2,24,351 | 26.07 | 2.60% | 0.02%↑ |
| Neuland Laboratories Ltd. | Healthcare | 11,278 | 24.08 | 2.40% | -0.48%↓ |
| Dr. Lal Pathlabs Ltd. | Healthcare | 1,09,504 | 21.76 | 2.17% | -0.18%↓ |
| CORONA Remedies Ltd. | Healthcare | 1,03,396 | 21.64 | 2.16% | -0.19%↓ |
| Thyrocare Technologies Ltd. | Healthcare | 3,94,514 | 21.07 | 2.10% | -0.21%↓ |
| Aurobindo Pharma Ltd. | Healthcare | 1,15,954 | 19.39 | 1.93% | -0.27%↓ |
| Ajanta Pharma Ltd. | Healthcare | 51,455 | 18.63 | 1.86% | 0.14%↑ |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 2,29,237 | 17.11 | 1.71% | -0.21%↓ |
| Max Healthcare Institute Ltd. | Healthcare | 1,83,812 | 17.09 | 1.70% | -1.35%↓ |
| Shaily Engineering Plastics Ltd. | Materials | 55,537 | 17.01 | 1.70% | -0.32%↓ |
| Global Health Ltd. | Healthcare | 1,23,468 | 16.85 | 1.68% | -0.24%↓ |
| Narayana Hrudayalaya Ltd. | Healthcare | 83,394 | 14.94 | 1.49% | -0.27%↓ |
1 / 3
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 30 Sep 2026 | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 85.96% | 93.32% | 93.56% | 87.96% | 94.12% | 93.65% |
| Chemicals | 2.66% | 2.88% | 3.40% | 2.59% | 2.49% | 3.24% |
| Materials | 1.70% | 2.01% | 1.39% | 1.26% | 1.75% | 1.31% |
| Services | 1.11% | 1.10% | 0.85% | 0.80% | 0.74% | 0.96% |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
22.5 / 100
Weighted average Value score is 22.5. This indicates that portfolio is relatively overvalued using composite of value measures.
Price Momentum score
66.8 / 100
Weighted average Price Momentum score is 66.8. This indicates that portfolio has average momentum using composite of momentum measures.
Quality score
81.1 / 100
Weighted average Quality score is 81.1. This indicates that portfolio has high quality using composite of quality measures.
QVM score
66.4 / 100
Weighted average QVM score is 66.4. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.
Red Flags
Frequently Asked Questions
What are the top holdings of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The top holdings of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth as of 30 Sep 2026 are Divis Laboratories Ltd. (7.73%), Sun Pharmaceutical Industries Ltd. (6.57%), Torrent Pharmaceuticals Ltd. (5.78%), Others (5.13%), Laurus Labs Ltd. (3.61%). These top 5 stocks together account for 28.83% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does WhiteOak Capital Pharma and Healthcare Fund Direct-Growth hold in its portfolio?
WhiteOak Capital Pharma and Healthcare Fund Direct-Growth holds 60 stocks in its portfolio as of 30 Sep 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
As of 30 Sep 2026, WhiteOak Capital Pharma and Healthcare Fund Direct-Growth's top sector allocations are Healthcare (85.96%), Chemicals (2.66%), Materials (1.70%). You can find detailed sector allocation above.
What is the equity and debt allocation of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
As of 30 Sep 2026, WhiteOak Capital Pharma and Healthcare Fund Direct-Growth has 91.43% allocated to equity, and 8.04% to debt. You can also check the historical trends above.
What is the market cap allocation of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
As of 30 Sep 2026, WhiteOak Capital Pharma and Healthcare Fund Direct-Growth's market cap allocation is 32.14% in large caps, 24.51% in mid caps, and 43.35% in small caps.
What is the PE ratio of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth's portfolio?
The portfolio PE ratio of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth is 50.96 as of 30 Sep 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
A credit rating breakdown is not available for WhiteOak Capital Pharma and Healthcare Fund Direct-Growth — its non-equity allocation was 8.04% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The latest portfolio disclosure for WhiteOak Capital Pharma and Healthcare Fund Direct-Growth is as of 30 Sep 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.